Schonfeld Strategic Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.53M	Buy	416,869 +332,313	+393%	+$1.11M	0.01%	1214
2026 Q1	$260K	Buy	+84,556	New	+$327K	﹤0.01%	1638
2025 Q3	–	Sell	-21,371	Closed	-$108K	–	2525
2025 Q2	$108K	Buy	+21,371	New	+$105K	﹤0.01%	1835
2025 Q1	–	Sell	-54,511	Closed	-$368K	–	2461
2024 Q4	$368K	Buy	+54,511	New	+$366K	﹤0.01%	1528
2023 Q1	–	Sell	-81,204	Closed	-$626K	–	2577
2022 Q4	$626K	Sell	81,204 -35,807	-31%	-$351K	0.01%	1404
2022 Q3	$1.24M	Sell	117,011 -55,184	-32%	-$559K	0.01%	1132
2022 Q2	$1.4M	Buy	172,195 +81,395	+90%	+$545K	0.01%	867
2022 Q1	$650K	Buy	+90,800	New	+$965K	0.01%	1218

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Schonfeld Strategic Advisors's RXRX Position: Q2 2026 in Review

Schonfeld Strategic Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 393% in Q2 2026, buying an estimated $1.11M and bringing the position to 416,869 shares worth $1.53M. The position accounts for 0.01% of the portfolio, ranked #1214.

Schonfeld Strategic Advisors first reported a position in RXRX in Q1 2022 and has held it in 8 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Schonfeld Strategic Advisors held 416,869 shares of Recursion Pharmaceuticals worth $1.53M as of Q2 2026.
Schonfeld Strategic Advisors bought 332,313 Recursion Pharmaceuticals shares in Q2 2026, an estimated $1.11M.
Recursion Pharmaceuticals made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1214 holding.
Schonfeld Strategic Advisors first reported a position in Recursion Pharmaceuticals in Q1 2022 and has held it in 8 quarters since.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.